During the median follow-up period of 50 months (interquartile range, 23–66 months), we confirmed 49 cardiovascular events (18 in the low A-FABP group and 31 in the high A-FABP group), including 16 cardiovascular deaths (5 in the low A-FABP group and 11 in the high A-FABP group), 6 strokes (4 in the low A-FABP group and 2 in the high A-FABP group), 18 revascularizations (7 in the low A-FABP group and 11 in the high A-FABP group), and 9 hospitalizations for heart failure (2 in the low A-FABP group and 9 in the high A-FABP group). Here, FABP4 is linked to heart failure.